In this issue:
Antivirals and liver-related complications in HDV
Viekira Pak during haemodialysis, in HCV and liver fibrosis
Time to viral suppression not related to SVR12 in HCV GT-1 treated with Viekira Pak ±RBV
Effects of HCV NS5A polymorphisms on elbasvir, grazoprevir efficacy
Ledipasvir + sofosbuvir for 8 or 12 weeks in HCV GT-2
RG-101 (miR-122 antagonist) for HCV
Week 4 viral load predicts long-term HBV DNA suppression during antiviral therapy
DAAs effectively treat elderly HCV-infected patients
Shortened DAA regimens effective in multiple GTs
HCV re-infection incidence posttreatment for recent infection
Please login below to download this issue (PDF)